Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects

Cancer Letters

Volumn 377, Issue 2, 2016, Pages 164-173

  Li, Dong ^a   Xie, Kun ^a   Zhang, Longzhen ^a   Yao, Xuejing ^a   Li, Hongwen ^a   Xu, Qiaoyu ^b   Wang, Xin ^a   Jiang, Jing ^b   Fang, Jianmin ^a,b,c,d  

^a TONGJI UNIVERSITY   (China)

^b Yantai RC Biotechnologies   (China)

^c SOOCHOW UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Anti angiogenic therapy; Cancer therapy; Dual decoy receptor; FGF 2; VEGF

Indexed keywords

CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; A-549 CELL LINE; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL MOTION; CHO CELL LINE; COMPLICATION; CRICETULUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HYPEROXIA; LUNG NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; RETINA BLOOD VESSEL; RETINAL NEOVASCULARIZATION; SIGNAL TRANSDUCTION; TIME FACTOR; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

A549 CELLS; ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HYPEROXIA; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT FUSION PROTEINS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84965164363     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.04.036     Document Type: Article

References (36)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Campochiaro P.A. Ocular neovascularization. J. Mol. Med 2013, 91:311-321.
3. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol 2007, 62:179-213.
4. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res 2003, 22:1-29.
5. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
6. Compagni A., Wilgenbus P., Impagnatiello M.A., Cotten M., Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000, 60:7163-7169.
7. Saylor P.J., Escudier B., Michaelson M.D. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin. Genitourin. Cancer 2012, 10:77-83.
8. Sun X.T., Ding Y.T., Yan X.G., Wu L.Y., Li Q., Cheng N., et al. Angiogenic synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in an in vitro quantitative microcarrier-based three-dimensional fibrin angiogenesis system. World J. Gastroenterol 2004, 10:2524-2528.
9. Giavazzi R., Sennino B., Coltrini D., Garofalo A., Dossi R., Ronca R., et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am. J. Pathol 2003, 162:1913-1926.
10. Teicher B.A. Antiangiogenic agents and targets: a perspective. Biochem. Pharmacol 2011, 81:6-12.
11. Cohen M.H., Gootenberg J., Keegan P., Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007, 12:713-718.
12. Cohen M.H., Shen Y.L., Keegan P., Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14:1131-1138.
13. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11393-11398.
14. Lutty G.A., McLeod D.S., Bhutto I., Wiegand S.J. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest. Ophthalmol. Vis. Sci 2011, 52:4039-4047.
15. FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer. Oncology 2012, 26:842. 873.
16. Stewart M.W. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev. Clin. Pharmacol 2013, 6:103-113.
17. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res 2008, 14:6371-6375.
18. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
19. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
20. Gyanchandani R., Ortega Alves M.V., Myers J.N., Kim S. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol. Cancer Res 2013, 11:1585-1596.
21. Dorrell M.I., Aguilar E., Scheppke L., Barnett F.H., Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:967-972.
22. Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol 2010, 28:453-459.
23. Allen E., Walters I.B., Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin. Cancer Res 2011, 17:5299-5310.
24. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol 2008, 20:460-470.
25. Harding T.C., Long L., Palencia S., Zhang H., Sadra A., Hestir K., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med 2013, 5:178ra139.
26. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., Amato R.D., Sullivan R., et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci 1994, 35:101-111.
27. Li D., Wei X., Xie K., Chen K., Li J., Fang J. A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br. J. Cancer 2014, 111:68-77.
28. Ferrara N., Chen H., Davis-Smyth T., Gerber H.P., Nguyen T.N., Peers D., et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med 1998, 4:336-340.
29. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med 1999, 5:623-628.
30. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol 1998, 141:1659-1673.
31. Gabler C., Plath-Gabler A., Killian G.J., Berisha B., Schams D. Expression pattern of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) system members in bovine corpus luteum endothelial cells during treatment with FGF-2, VEGF or oestradiol. Reprod. Domest. Anim 2004, 39:321-327.
32. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res 2006, 12:5018-5022.
33. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl. 1):2-10.
34. Kuhn M.C., Willenberg H.S., Schott M., Papewalis C., Stumpf U., Flohe S., et al. Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation. Mol. Cell. Endocrinol 2012, 349:180-188.
35. Connor K.M., Krah N.M., Dennison R.J., Aderman C.M., Chen J., Guerin K.I., et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc 2009, 4:1565-1573.
36. Stahl A., Paschek L., Martin G., Feltgen N., Hansen L.L., Agostini H.T. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch. Clin. Exp. Ophthalmol 2009, 247:767-773.